Dana-Farber Cancer Institute | Strategic Alliance Partners

April 16, 2020

Guru P. Sonpavde, MD sheds light on how the COVID-19 pandemic has impacted treatment decisions for patients with bladder cancer, perioperative surgical concerns for patients at risk of COVID-19, and the preventative measures Dana-Farber Cancer Institute has put into place to reduce the risk of patients and providers contracting the virus.

April 16, 2020

Corey S. Cutler, MD, MPH, FRCPC, discusses some of the novel preventive strategies against graft-versus-host disease.

April 08, 2020

Himisha Beltran, MD, discusses the utility of liquid biopsies versus tissues biopsies in castration-resistant neuroendocrine prostate cancer.

April 07, 2020

The addition of acalabrutinib (Calquence) to venetoclax (Venclexta) and obinutuzumab (Gazyva) was shown to be highly active in patients with newly diagnosed chronic lymphocytic leukemia, eliciting deep and durable responses.

April 07, 2020

Sara M. Tolaney, MD, MPH, discusses remaining sequencing questions in breast cancer.

April 07, 2020

David P. Steensma, MD, discusses some new data in myelodysplastic syndromes and ongoing research in the space.

April 03, 2020

Anis Hamid, MBBS, genitourinary oncology research fellow, Dana-Farber Cancer Institute, discusses the evolution of precision medicine in prostate cancer.

April 02, 2020

Nancy U. Lin, MD, discusses central nervous system activity with HER2-directed TKIs in HER2-positive breast cancer.

April 02, 2020

Ziad Bakouny, MD, MSc, discusses the utility of checkpoint inhibitors in renal cell carcinoma with sarcomatoid differentiation.

April 01, 2020

Lynette M. Sholl, MD, discusses the evolving use of liquid and tissue biopsies for next-generation sequencing in the treatment paradigm for patients with lung cancer.

March 30, 2020

Bradley McGregor, MD, discusses the CheckMate-9ER trial in metastatic renal cell carcinoma, as well as the need for future studies in histologies beyond clear cell renal cell carcinoma.

March 28, 2020

Jacqueline S. Garcia, MD, discusses results from a phase II trial examining the addition of the BCL-2/BCL-XL inhibitor navitoclax to ruxolitinib in patients with primary or secondary myelofibrosis with acquired resistance to ruxolitinib.

March 26, 2020

David P. Steensma, MD, discusses the potential utility of venetoclax in myelodysplastic syndrome.

March 25, 2020

Toni K. Choueiri, MD, highlights the changes he has observed in clinical practice amidst the COVID-19 pandemic and the unified approach being taken at Dana-Farber Cancer Institute.

March 24, 2020

Corey S. Cutler, MD, MPH, FRCPC, discusses methods to optimize treatment for patients with acute and chronic graft-versus-host disease.

March 23, 2020

Reid W. Merryman, MD, discusses the impact of adding high-dose cytarabine to bendamustine and rituximab as an induction regimen for patients with mantle cell lymphoma.

March 23, 2020

Jacqueline S. Garcia, MD, discusses unmet needs for patients with myelofibrosis who progress on JAK inhibitors.

March 20, 2020

Himisha Beltran, MD, discusses research evaluating cell-free DNA to identify therapy resistance in prostate cancer.

March 20, 2020

Anis Hamid, MBBS, discusses the hypothesis of predictive biomarkers for newly diagnosed metastatic hormone sensitive prostate cancer.

March 19, 2020

Lynette M. Sholl, MD, discusses the challenges faced with the use of tissue biopsy to test for biomarkers in lung cancer.